EFFICACY OF IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (IRD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AFTER ≥3 PRIOR LINES OF THERAPY: A REAL-WORLD SINGLE-CENTER EXPERIENCE
EHA Library, Yuliia Makarets,
4209911
TREATMENT OF HIGH-RISK SMOLDERING MULTIPLE MYELOMA (HRSMM) WITH ISATUXIMAB, LENALIDOMIDE, ORAL CYCLOPHOSPHAMIDE AND DEXAMETHASONE: A SURVIVAL ADVANTAGE IN A CASE SERIES STUDY
EHA Library, Maher Salamoon,
4209918
A MODERN THROMBOSIS RISK MODEL FOR MYELOPROLIFERATIVE NEOPLASMS: INTEGRATING INFLAMMATION, MOLECULAR MARKERS, AND SPLENIC BIOLOGY IN SINGLE CENTER REAL-WORLD COHORT.
EHA Library, Nouran Alhashimi,
4209948
DARATUMUMAB-BASED THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA: A SINGLE-CENTER REAL-WORLD STUDY OF DYNAMIC TRANSPLANT ELIGIBILITY, DEEP RESPONSE, AND PROGNOSIS IN THE 2025 IMS-IMWG ERA
EHA Library, Lijing Shen,
4209864
MOMENTUM: A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFICACY OF CEMSIDOMIDE + DEXAMETHASONE IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Library, Binod Dhakal,
4209937